Actions of sodium valproate on the central nervous system

Journal of Physiology and Pharmacology

Volumn 50, Issue 3, 1999, Pages 347-365

  Tunnicliff, G ^a  

^a Indiana University School of Medicine Evansville   (United States)

Author keywords

Epilepsy; GABA; Migraine headaches; Mood disorders; Na+ channels; Valproate

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; EXCITATORY AMINO ACID RECEPTOR; SODIUM CHANNEL; VALPROIC ACID;

AFFECTIVE NEUROSIS; ANTICONVULSANT ACTIVITY; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER TOXICITY; MIGRAINE; NEUROTRANSMISSION; NONHUMAN; PETIT MAL; REVIEW;

ANIMALS; ANTICONVULSANTS; ANTIMANIC AGENTS; CENTRAL NERVOUS SYSTEM; GABA AGENTS; HUMANS; VALPROIC ACID;

EID: 0032873381     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Meunier G, Caraz G, Meunier Y, Eymard P, and Aimard M. Properiétés pharmacodynamiques de l'acide n-dipropylacétique. Therapie 1963; 18: 435-438.
2. Rothrock JF. Clinical studies of valproate for migraine prophylaxis. Cephalagia 1997; 17: 81-83.
3. Pope HG, McElroy SL, and Keck PE. Valproate in the treatment of acute mania. Arch Gen Psychiatr 1991: 62-68.
4. Keck PE, Taylor VE, Tugrul KC, McElroy SK, Bennett JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatr 1993; 33: 542-546.
5. Chapman A, Keane PE, Meldrum BS, Simiand J and Verniers JC. Mechanism of anticonvulsant action of valproate. Progr Neurobiol 1982; 19: 315-359.
6. Fariello RG, Varasi M, Smith MC. Valproic acid: Mechanisms of action. In Antiepileptic Drugs, Levy RH, Mattson RH, Meldrum BS, (eds.). Raven Press. 1995, pp. 581-588.
7. Krnjevic K. Significance of GABA in brain function. In GABA Mechanisms in Epilepsy, Tunnicliff G, Raess BU. (eds.). New York, Wiley-Liss, 1991, pp. 47-87.
8. Wood JD. The role of γ-aminobutyric acid in the mechanism of seizures. Progr Neurobiol, 1975; 5: 77-95.
9. Kash SF, Johnson RS, Tecott LH, Noebels JL, Mayfield RD, Hanahan D, and Baekkeskov S. Epilepsy in mice deficient in the 65-Kda isoform of glutamic acid decarboxylase. Proc Natl Acad USA 1997; 94: 14060-14065.
10. Tunnicliff G, Raess BU. GABA neurotransmitter activity in human epileptogenic brain. In GABA Mechanism in Epilepsy, Tunnicliff G, Raess BU (eds.). New York, Wiley-Liss, 1991, pp. 105-119.
11. Godin Y, Heiner L, MArk J, Mandel P. Effects of di-n-propylacetate, an anticonvulsive compound, on GABA metabolism. J Neurochem 1969; 16: 869-873.
12. Simler S, Ciesielski L, Maitre M, Randrianarisoa H, Mandel P. Effect of sodium n-dipropylacetate on audiogenic seizures and brain γ-aminobutyric acid level. Biochem Pharmacol 1973; 1701-1708.
13. Patsalos PN, Lascelles PT. Changes in regional brain levels of amino acid putative neurotransmitters after prolonged treatment with the anticonvulsant drugs diphenylhydantoin, phenobarbitone, sodium valproate, ethosuximide and sulthiame in the rat. J Neurochem 1981; 36: 688-695.
14. Löscher W, Siemes H. Valproic acid increases gamma-aminobutyric acid in CSF of epileptic children. Lancet 1984; II: 225.
15. Fowler LJ, Beckford J, Johb RA. An analysis of the kinetics of the inhibition of rabbit brain γ-aminobutyrate aminotransferase by sodium-n-dipropylacetate and some other simple carboxylic acids. Biochem Pharmacol 1975; 24: 1267-1270.
16. Anlezark G, Horton RW, Meldrum BS, Sawaya MCB. Anticonvulsant action of ethanolamine-O-sulphate and di-n-propylacetate and the metabolism of γ-aminobutyric acid (GABA) in mice with audiogenic seizures. Biochem Pharmacol 1976; 25: 413-417.
17. Löscher W. In vivo administration of valproate reduces the nerve terminal (synaptosomal) activity of GABA aminotransferase in discrete brain areas of rats. Neurosci Letts 1993; 160: 177-180.
18. Larsson OM, Gram L, Schousboe I, Schousboe A. Differential effects of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurons and astrocytes. Neuropharmacology 1986; 25: 617-625.
19. Emson PC. Effects of chronic treatment with amino oxyacetic acid or sodium n-dipropylacetate on brain GABA levels and the development and regression of cobalt epileptic foci in rats. J Neurochem 1976; 27: 1498-1494.
20. Löscher W, Nau H. Valproic acid: metabolite concentrations in plasma and brain, anticonvulsant activity, and effects on GABA metabolism during subacute treatment in mice. Arch Int Pharmacodyn Ther 1982; 257: 20-31.
21. Nau H, Löscher W. Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and γ-aminobutyric acid (GABA) metabolism in the mouse. J Pharmacol Exp Ther 1982; 220: 654-659.
22. Hearl HG, Churchich JE. Interactions between 4-aminotransferase and succinic semialdehyde dehydrogenase, two mitochondrial enzymes. J Biol Chem 1984; 259: 11459-11463.
23. Harvey PK, Bradford HF, Davison AN. The inhibitory effect of sodium n-dipropylacetate on the degradative enzymes of the GABA shunt. FEBS Lett 1975; 52: 251-254.
24. Van der Laan JW, De Boer T, Brunvels J. Di-n-propylacetate and GABA degradation: preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase. J Neurochem 1979; 32: 1769-1780.
25. Maitre M, ossala L, Mandel P. In vitro studies into the effect of inhibition of rat brain succinic semidaldehyde dehydrogenase on GABA synthesis and degradation. FEBS Lett 1976; 72: 53-57.
26. Pinder RM, Brogden RN, Speoght TM, Avery GS. Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs 1977; 13: 81-123.
27. Vajda FJE, Donnan GA, Phillips T, Bladin PF. Human brain, plasma and cerbrospinal fluid concentration of sodium valproate after 72 hr of therapy. Neurology 1981; 31: 1364-1366.
28. Löscher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem Pharmacol 1981a; 30: 1364-1366.
29. Löscher W. Effect of inhibitors of GABA aminotransferase on the metabolism of GABA in brain tissue and synaptosomal fractions. J Neurochem 1981b; 36: 1521-1527.
30. Phillips NI, Fowler LJ. The effects of sodium valproate on γ-aminobutyrate metabolism and behaviour in naive and ethanolamine-O-sulphate pretreated rats and mice. Biochem Pharmacol 1982; 31: 2257-2261.
31. Löscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res 1987; 501: 198-203.
32. Tabener PV, Charington CB, Unwin JW. Effects of GAD and GABA-T inhibitors on GABA metabolism invivo. Brain Res Bull 1980; 5: 621-625.
33. Cremer JE, Sarna GS, Teal HM, Cunningham VJ. Amino acid precursors: their transport into brain and initial metabolism. In Amino Acids as Transmitters, Fonnum F, (eds.) New York Plenum Press, 1978, pp. 6690-689.
34. 14C)-glucose into amino acids. Neurochem Res 1982: 7: 1089-1105.
35. Tunnicliff G. Significance of γ-hydroxybutyric acid in the brain. Gen Pharnacol 1992; 23: 1027-1034.
36. Whittle SR, Turner AJ. Effects of the anticonvulsant sodium valproate on γ-aminobutyrate and aldehyde metabolism in ox brain. J Neurochem 1978; 31: 1453-1459.
37. Andriamampandry C, Siddert JC, Schmitt M, GArnier JM, Staub A, Muller C, Govaille S, Mark J, Maitre M. Cloning of a rat brain succinic semialdehyde reductase involved in the synthesis of the neuromodulator γ-hydroxybutyrate. Biochem J 1998; 334: 43-50.
38. Chen G, Yuan PX, Hawver DB, Potter WZ, Manji HK. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology 1997; 16: 238-245.
39. Asghari V, Wang JF, Reiach JS, Young LT. Differential effects of mood stabilizers on Fas/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY-5Y cells. Mol Brain Res 1998; 58: 95-102.
40. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72: 1327-1330.
41. Chen G, Zen WZ, Yuang PX, Huang LD, Jiang YM, Zhao ZH, Manji HK. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999; 72: 879-882.
42. Jacobson MD, Raff M. Programmed cell death and Bcl-2 protection in very low oxygen. Nature 1995; 374: 814-816.
43. Chen DF, SChneeider GE, Maetinou JC, Tonegawa S. Bcl-2 promotes regeneration of severed axons in mammalian CNS. Nature 1997; 385: 434-439.
44. 2+-valproate in cultured cerebellar neurons. Funct Neurol 1995; 10: 121-130.
45. Chen G, Manji HK, Wright CB, Hawver DB, Potter WZ. Effects of valproic acid on β-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology 1996; 15: 271-280.
46. McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in culture. J Pharmacol Exp Ther 986; 237: 1001-1011.
47. Nosek TM. Depression of axonal excitability by valproate is antagonized by phenytoin. Epiepsia 1981; 22: 641-650.
48. Van Dongen AMJ, Van Erp MG, Voskuyl RA. Valproate reduces excitability by blockage of sodium and potassium conductance. Epilepsia 1986; 27: 177-182.
49. Zona C, Avoli M. Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture. Exp Brain Res 1990; 81: 313-317.
50. Van der Berg RJ, Kok P, Voskuyl RA. Valproate and sodium currents in cultured hippocampal neurons. Exp Brain Res 1993; 93: 279-287.
51. Taverna S, Mantegazza M, Franceschetti S, Avanzini G. Valproate selectively reduces the persistent fraction of Na+ current in neocortical neurons. Epilepsy Res 1998; 32: 304-308.
52. Yamamoto R, Yanagita T, Kobayashi H, Yokoo H, Wada A. Up-regulation of sodium channel subunit mRNAs and their cell surface expression by antiepileptic valproic acid: Activation of calcium channel and catecholamine secretion in adrenal chromaffin cells. J Neurochem 1997; 68: 1655-1662.
53. 3H]batrachotoxinin A 20-αbenzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol 1982; 22: 627-635.
54. Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol 1984; 25: 228-234.
55. Macdonald RL, Bergey GK. Valproic acid augments GABA-mediated postsynaptic inhibition in cultured mammalian neurones. Brain Res 1979; 170: 558-562.
56. Harrison NL, Simmonds MA. Sodium valproate enhances responses to GABA receptor activation only at high concentrations. Brain Res 1982; 250: 201-204.
57. Gent JP, Phillips NI. Sodium di-n-propylacetate (valproate) potentiates responses to GABA and muscimol in single central neurones. Beain Res 1980; 197: 275-278.
58. Kerwin RW, Olpe HR. Schmutz M. The effect of sodium-n-dipropylacetate on α-aminobutyric acid-dependent inhibition in the rat cortex and substantia nigra in relation to its anticonvulsant activity. Br J Pharmacol 1980; 71: 545-551.
59. Hayashi T, Negishi K. Suppression of retinal spike discharge by dipropylacetate (Depakene): a possible involvement of GABA. Brain Res 1979; 175: 271-278.
60. Baldino F, Geller HM. Sodium valproate enhancement of gamma-aminobutyric acid (GABA) inhibition: electrophysiological evidence for anticonvulsant activity. J Pharmacol Exp Ther 1981; 217: 445-450.
61. Baldino F, Geller HM. Effect of sodium valproate on hypothalamic neurons in vivo and in vitro. Brain Res 1981; 219: 231-237.
62. A-mediated inhibition of locus coerulus neruones in vitro. Naunyn-Schiedeberg's Arch Pharmacol 1988; 338: 655-657.
63. Wolf R, Tscherne U, Emrich HM. Suppression of preoptic GABA release caused by push-pull-perfusion with sodium valproate. Naunyn-Schmiedeberg's Arch Pharmacol 1988; 338: 658-663.
64. Ko GY, Brown-Croyts LM, Teyler TJ. The effects of anticonvulsant drugs on NMDA-EPSP, AMPA-EPSP and GABA-IPSP in the rat hippocampus. Brain Res Bull 1997; 42: 297-302.
65. Hackmsn JC, Grayson V, Davidoff RA. The presynaptic effects of valproic acid in the isolated frog spinal cord. Brain Res 1981; 220: 269-285.
66. Rowley HL, Marsden CA, Martin KF. Differential effects of phenytoin and sodium valproate on seizure-induced changes in α-aminobutyric acid and glutamate release in vivo. Eur J Pharmacol 1995; 294: 541-546.
67. Blume HW, Lamour Y, Arnauld E, Layton BS, Renaud LP. Sodium di-n-propylacetate (valproate) action on single neurons in rat cerebral cortex and hippocampus. Brain Res 1979; 171: 182-185.
68. Czuczwar SJ, Meldrum B. Protection against chemically induced seizures by 2-amino-7-phosphoheptanoic acid. Eur J Pharmacol 1982; 83: 335-3.
69. De Sarro GB, De Sarro A. Anticonvulsant properties of non-competitive antagonists of the N-methyl-D-aspartate receptor in genetically epilepsy-prone rats: comparison with CPPene. Neuropharmacology 1993; 32: 51-58.
70. Czuczwar SJ, Frey HH, Loscher W. Antagonism of N-methyl-D,L-aspartic acid-induced convulsions by antiepileptic drugs and other agents. Eur J Pharmacol 1985; 108: 273-2.
71. 3H]norepinephrine efflux. Eur J Pharmacology 1994; 254: 307-309.
72. Zeise ML, Kasparow S, Zieglgansverger W. Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res 1991; 544: 345-348.
73. 3H]α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid [AMPA] binding by the anticonvulsant valproate in clinically relevant concentrations: an autoradiographic investigation in human hippocampus. Epilepsy Res 1998; 31: 153-157.
74. Kukino K, Deguchi T. Effects of sodium dipropylacetate on α-aminobutyric acid and biogenic amines in rat brain. Chem Pharm Bull 1977; 25: 2257-2262.
75. Williams RJH, Patsalos PN, Lowe R, Lascelles PT. Changes in brain amino acid neurotransmitters induced by sodium valproate and their relevance to epilepsy and interactions with other anticonvulsants. In The Place of Sodium Valproate in the Treatment of Epilepsy London Academic Press, 1980, pp. 95-102.
76. Schechter PJ, Tranier Y, Grove J. Effect of n-dipropylacetate on amino acid concentrations in mouse brain: corelation with anti-convulsant activity. J Neurochem 1978; 31: 1325-1327.
77. Chapman AG, Croucher MJ, Meldrum BS. Anticonvulsant activity of intracerebroventricularly administered valproate and valproate analogues. A dose-dependent correlation with changes in brain aspartate and GABA levels in DBA/2 mice.ź Biochem Pharmacol 1984; 33: 1459-1463.
78. Perry T, Hansen S. Biochemical effects in man and rat of three drugs which can increase brain GABA content. J Neurochem 1978; 30: 679-684.
79. 2+uptake and amino acid neurotransmitter release in vitro. Epilepsia 1987; 28: 378-382.
80. Zhang YF, Gibbs JW, Coulter DA. Anticonvulsant drug effects on spontaneous thalamocortical rhythms in vitro: valproic acid, clonazepam and alpha-methyl-alpha-phenylsuccinimide. Eoilepsy Res 1996; 23: 37-53.
81. Schmutz M, Olpe HR, Koella WP. Central actions of valproate sodium. J Pharm Pharmacol 1919; 31: 1325-1327.
82. Salt TE, Tulloch IF, Walrwe DS. Anti-epileptic properties of sodium valproate in rat amygdaloid kindling. Br J Pharmacol 1980; 68: 34P.
83. Kelly KM, Gross RA, Macdonald RL. Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons. Neurosci Lett 1990; 116: 233-238.
84. Agopyan N, Avoli H, Rieb L, Tancredi V. Depression of hippocampal low calcium field bursts by the antiepileptic drug valproic acid. Neurosci Lett 1985; 60: 57-62.
85. +] in the hippocampal slice. Brain Res 1986;386: 1-11.
86. Slater GE, Johnston GD. Sodium valproate increases potassium conductance in Aplusia neurones. Epilepsia 1978; 19: 379-384.
87. Chen G, Manji HK, Wright CB, Hawver DB, Potter WZ. Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychoparmacology 1996; 15: 271-280.
88. Sorensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand 1988; 78: 346-348.
89. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 12: 81-84.
90. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994; 44: 647-651.
91. Lenaerts M, Bastings E, Sianard J, Schoenen J. Sodium valproate in severe migraine and tension-type headache: an open study of long-term efficacy and correlation with blood levels. Acta Neurol Belg 1996; 96: 126-129.
92. Mathew N, Saper J, Silberstein S, Rankin L, Markley HG, Solomon S et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52: 281-286.
93. Klapper JA. Divalproex sodium in migraine prophylaxis study group: A dose -controlled study. Cephalalgia 1997; 17: 103-108.
94. Weber RB, Reinmuth OM. The treatment of migraine with propanolol. Neurology 1972; 22: 336-369.
95. Kaniecki R. A comparison of divalproex with propanolol and placebo for the prophylaxis of migraine without aura. Archh Neurol 1997; 54: 1141-1145.
96. Harrow M, Goldberg JF, Grossman LS, Meltzer HY. Outcome in manic disorders. Arch Gen Psychiatry 1990; 47: 665-671.
97. Maj M, Priozzi R, Kemali D. Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology 1989; 98: 535-538.
98. Lambert PA, Cavaz G, Borselli S, Carrel S. Action neuropsychotrope d'un nouvel antiépileptique: Le Dépamide. Ann Med Psychol 1966; 1: 707-710.
99. Emrich HM, Von Zerssen D, Kissling W, Moller HJ, Windorfer A. Effect of sodium valproate in mania. The GABA hypothesis of afective disorders. Arch Psychiatr Nervenkr 1980; 229: 1-16.
100. Bowden C, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. J Am Med Assoc 1994; 271: 918-924.
101. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiat 1990; 147: 431-434.
102. Lambert PA. Venaud G. Comparative study of valpromide versus lithium as prophylactic treatment in affective disorders. Nervure J Psychiat 1995; 7: 1-9.
103. Denicoff KD, Smith-Jackson EE, Bryan AL, Ali SO, Post RM. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997; 154: 1456-1458.
104. Prien RF, Himmelhoch JM, Kupfer DJ. Treatment of mixed mania. J Affect Disord 1988; 15: 9-15.
105. Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J et al. Depression during mania: Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997; 54: 37-42.
106. Dixon JF, Hokin LE. The antibipolar drug valproate mimics lithiun in stimulating glutamate release and inositol 1,4,5-triphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and biphosphates. Proc Natl Acad Sci USA 1997; 94: 4757-4760.
107. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshelman S, et al. Lifetime and 12 month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatr 1994; 51: 8-19.
108. Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J OPsychiatr 1990; 35: 248-250.
109. Keck PE, Taylor VE, Tugrul KC, McElroy SL, Bennett JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatr 1993; 33: 542-546.
110. Woodman C, Noyes R. Panic Disorder: treatment with valproate. J Clin Psychiatr 1994; 55: 134-136.
111. Baetz M, Bowen RC. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatr 1998; 43: 73-77.
112. Shoulson I, Kartzinel R, Chase TN. Huntingtons's disease: Treatment with dipropylacetic acid and gamma-aminobutyric acid. Neurology 1976; 26: 61-63.
113. Dreifuss FE, Santili N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: A retrospective reviev. Neurology 1987; 37: 379-385.
114. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: Analyses of 23 fatal cases. Hepatology 1982; 2: 591-597.
115. Mortensen PB, Gregersen N, Kolvraa S, Christensen E. The occurrence of C6-C10-dicarboxylic acids in urine from patients and rats treated with dipropylacetate. Biochem Med 1980; 24: 153-161.
116. Coulter DL, Allen RJ. Secondary hyperammonaemia: A possible mechanism for valproate encephalopathy. Lancet 1980; 1: 1310-1311.
117. Rawat S, Borkowski Wj, Swick HM. Valproic acid and secondary hyperammonemia. Neurology 1981; 31: 1173-1174.
118. Zaccara G, Campostrini R, Paganini M, Moroni F, Valenza T, Targioni G, et al. Acute changes of blood ammonia may predict short-term adverse effects of valproic acid. Neurology 1984; 34: 1519-1521.
119. Becker CM, Harris RA. Influence of valproic acid on hepatic carbohydrate and lipid metabolism. Arch Biochem Biophys 1983: 223: 381-392.
120. Turnbull DM, Bone AJ, Bartlett K, Koundakjian PP, Sherratt HSA. The effects of valproate on intermediary metabolism in isolated rat hepatoocytes and intact rats. Biochem Pharmacol 1983; 32: 1887-1892.
121. Bjorge SM, Bailie TA. Inhibition of medium-chain fatty acid β-oxidation in vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid. Biochem Biophys Res Commun 1985; 132: 245-252.
122. Draye JP, Vamecq J. The inhibition by valproic acid of the mitochondiral oxidation of monocarboxylix and ω̃-hydroxymonocarboxylic acids: Possible implications for the metabolism of gamma-aminobutyric acid. J Biochem 1987; 102: 235-242.
123. Veitch K, Van Hoof F. In Vitro effects of eight-carbon fatty acids on oxidations in rat liver mitochondria. Biochem Pharmacol 1990; 40: 2153-2159.
124. Rogies V, Vandenberghe Y, Vercruysse A. Inhibition of gluconeogenesis by sodium valproate and its metabolites in isolated rat hepatocytes. Xenobiotica 1985; 15: 759-765.
125. Cloudé FX, Grimber G, Parvy P, Rabier D, Petit F. Inhibition of ureagenesis by valproate in rat hepatocytes. Biochem J 1983; 216: 233-236.
126. Li J, Norwood DL, Mao LF, Schultz H. Mitochondiral metabolism of valproic acid. Biochemistry 1991; 30: 388-394.
127. Bjorge SM, Bailie TA. Studies of the β-oxidation of valproic acid in rat liver mitochondrial preparations. Drug Metab Disppos 1991; 19: 823-829.
128. Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathalogic studies. Hepatology 1984; 4: 1143-1152.
129. Granneman GR, Wang SI, Kesterson JW, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism. Hepatology 1984; 4: 1153-1158.
130. Geber N, Dickinson RG, Hartland RC, Lynn RK, Houghton D, Antonias JI. et al. Reye-like syndrome asociated with valproic acid therapy. J Pediatr 1979; 95: 142-144.
131. Rumbach L, Warter Jm, Rendon A, Marescaux C, Micheletti G, Waksman A. Inhibition of oxidative phosphorylation in hepatic and cerebral mitochondria of sodium valproate-treatmend rats. J Neurol 1983; 61: 417-423.
132. 3 depletion is the cause of the dificient intramitochondrial respiration induced by chronic valproale administration. Biochem Pharmacol 1992; 43: 644-647.